Efficacy and safety of rademikibart (CBP-201), a next-generation monoclonal antibody targeting IL-4Rα, in adults with moderate-to-severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001)
Efficacy and security of rademikibart (CBP-201), a next-generation monoclonal antibody ...